For the case of PXE, anti-vascular endothelial growth factor (anti-VEGF) is currently used as an off-label drug to treat macular neovascularization to slow progression of retinal disease and visual impairment. This evidence concerns the gene VEGFA and Pseudoxanthoma elasticum.